Faron Pharmaceuticals Oy Presentation at J.P. Morgan Healthcare Conference
January 03 2024 - 1:00AM
RNS Non-Regulatory
TIDMFARN
Faron Pharmaceuticals Oy
03 January 2024
Faron Pharmaceuticals Oy
("Faron" or "Company")
Faron Pharmaceuticals to Present at the 42(nd) Annual J.P.
Morgan Healthcare Conference
Press release
TURKU, FINLAND / BOSTON, MA - January 3, 2024 - Faron
Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical
stage biopharmaceutical company pursuing a CLEVER approach to
reprogramming myeloid cells to activate immunity in hematological
and solid tumor microenvironments, today announces that Dr. Markku
Jalkanen, Chief Executive Officer, will present at the 42nd Annual
J.P. Morgan Healthcare Conference on Thursday January 11, 2024, at
12pm PT, in San Francisco.
The presentation will be accessible through the "Investors"
section of the Company's website at www.faron.com and will be
available following the event.
About Faron Pharmaceuticals Ltd.
Faron (AIM: FARN, First North: FARON) is a global,
clinical-stage biopharmaceutical company, focused on tackling
cancers via novel immunotherapies. Its mission is to bring the
promise of immunotherapy to a broader population by uncovering
novel ways to control and harness the power of the immune system.
The Company's lead asset is bexmarilimab, a novel anti-Clever-1
humanized antibody, with the potential to remove immunosuppression
of cancers through targeting myeloid cell function. Bexmarilimab is
being investigated in Phase I/II clinical trials as a potential
therapy for patients with hematological cancers in combination with
other standard treatments treatments and as a monotherapy in last
line solid cancers . Further information is available at
www.faron.com.
For more information please contact:
Investor Contact
LifeSci Advisors
Daniel Ferry
Managing Director
daniel@lifesciadvisors.com
+1 (617) 430-7576
ICR Consilium
Mary-Jane Elliott, David Daley, Lindsey Neville
Phone: +44 (0)20 3709 5700
E-mail: Faron@consilium-comms.com
Cairn Financial Advisers LLP, Nomad
Sandy Jamieson, Jo Turner
Phone: +44 (0) 207 213 0880
Peel Hunt LLP, Broker
Christopher Golden, James Steel
Phone: +44 (0) 20 7418 8900
Sisu Partners Oy, Certified Adviser on Nasdaq First North
Juha Karttunen
Phone: +358 (0)40 555 4727
Jukka Järvelä
Phone: +358 (0)50 553 8990
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRADLLFBZFLXBBZ
(END) Dow Jones Newswires
January 03, 2024 02:00 ET (07:00 GMT)
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Apr 2024 to May 2024
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From May 2023 to May 2024